Literature DB >> 18476095

Azithromycin (zithromax).

J M McCarty1.   

Abstract

Azithromycin (Zithromax), Pfizer, Inc., New York, NY) is a 15-membered-ring macrolide and the first azalide antibiotic. It is distinguished from other macrolides by its rapid and extensive penetration into intracellular and interstitial tissue compartments, accompanied by prolonged tissue and serum half-lives. Azithromycin shares the gram-positive activity of erythromycin but is more potent against gram-negative organisms. For urethritis and cervicitis caused by Chlamydia trachomatis, azithromycin is effective and well tolerated in a single dose of 1 g, a regimen recommended by the CDC. A 5-day dosage regimen is available for the treatment of community-acquired respiratory-tract and skin and skin-structure infections caused by susceptible organisms. Azithromycin provides short-duration, high-compliance, cost-effective regimens that should improve outcomes.

Entities:  

Year:  1996        PMID: 18476095      PMCID: PMC2364499          DOI: 10.1155/S1064744996000415

Source DB:  PubMed          Journal:  Infect Dis Obstet Gynecol        ISSN: 1064-7449


  33 in total

1.  New macrolide antibiotics: azithromycin and clarithromycin.

Authors:  H C Neu
Journal:  Ann Intern Med       Date:  1992-03-15       Impact factor: 25.391

2.  In vitro evaluation of activities of azithromycin, erythromycin, and tetracycline against Chlamydia trachomatis and Chlamydia pneumoniae.

Authors:  L E Welsh; C A Gaydos; T C Quinn
Journal:  Antimicrob Agents Chemother       Date:  1992-02       Impact factor: 5.191

3.  The in vitro activity of some 14-, 15- and 16- membered macrolides against Staphylococcus spp., Legionella spp., Mycoplasma spp. and Ureaplasma urealyticum.

Authors:  D Felmingham; M J Robbins; M Sanghrajka; A Leakey; G L Ridgway
Journal:  Drugs Exp Clin Res       Date:  1991

4.  A controlled trial of a single dose of azithromycin for the treatment of chlamydial urethritis and cervicitis. The Azithromycin for Chlamydial Infections Study Group.

Authors:  D H Martin; T F Mroczkowski; Z A Dalu; J McCarty; R B Jones; S J Hopkins; R B Johnson
Journal:  N Engl J Med       Date:  1992-09-24       Impact factor: 91.245

5.  Doxycycline compared with azithromycin for treating women with genital Chlamydia trachomatis infections: an incremental cost-effectiveness analysis.

Authors:  D Magid; J M Douglas; J S Schwartz
Journal:  Ann Intern Med       Date:  1996-02-15       Impact factor: 25.391

Review 6.  Pharmacokinetic drug interactions of macrolides.

Authors:  P Periti; T Mazzei; E Mini; A Novelli
Journal:  Clin Pharmacokinet       Date:  1992-08       Impact factor: 6.447

7.  Incidence and cost of hospital admissions secondary to drug interactions involving theophylline.

Authors:  R A Hamilton; T Gordon
Journal:  Ann Pharmacother       Date:  1992-12       Impact factor: 3.154

Review 8.  Cost effectiveness of once-daily oral antimicrobial therapy.

Authors:  P Davey; S Parker
Journal:  J Clin Pharmacol       Date:  1992-08       Impact factor: 3.126

9.  Compliance with antibiotic therapy for Chlamydia trachomatis and Neisseria gonorrhoeae.

Authors:  B P Katz; B W Zwickl; V A Caine; R B Jones
Journal:  Sex Transm Dis       Date:  1992 Nov-Dec       Impact factor: 2.830

Review 10.  The new macrolide antibiotics: azithromycin, clarithromycin, dirithromycin, and roxithromycin.

Authors:  N Bahal; M C Nahata
Journal:  Ann Pharmacother       Date:  1992-01       Impact factor: 3.154

View more
  1 in total

Review 1.  Antibiotics for recurrent acute pharyngo-tonsillitis: systematic review.

Authors:  Holger Munck; Anders W Jørgensen; Tejs Ehlers Klug
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2018-04-13       Impact factor: 3.267

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.